41
Participants
Start Date
August 28, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
August 31, 2027
MB097
Live bacterial therapeutic for oral administration
Pembrolizumab
IV infusion
Vancomycin
Antibiotic
Centre Georges Francois Leclerc, Dijon
CHU de Lille - Hopital Claude Huriez, Lille
Centre Leon Berard, Lyon
AP-HM - Hopital de la Timone, Marseille
HCL Centre Hospitalier Lyon Sud, Pierre-Bénite
Istituto Europeo di Oncologia, Milan
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli
Istituto Clinico Humanitas, Rozzano
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Ramon y Cajal, Madrid
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC, Madrid
Consorcio Hospital General Universitario de Valencia, Valencia
Sussex Cancer Centre, Brighton
Addenbrooke's Hospital, Cambridge
Beatson West of Scotland Cancer Centre, Glasgow
The Royal Marsden NHS Foundation Trust, London
The Christie NHS Foundation Trust, Manchester
Freeman Hospital, Newcastle
Royal Marsden Hospital - Surrey, Sutton
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Microbiotica Ltd
INDUSTRY